COSMOS participants and COSMOS biomarker cohort
PsA
DISEASE CHARACTERISTIC
In COSMOS, 189 participants with active TNFi-IR PsA were randomized to receive guselkumab Q8W, and 96 participants were randomized to receive placebo followed by guselkumab. Of these, 100 and 50 participants, respectively, were included in the biomarker cohort. In the COSMOS biomarker cohort, 21/100 (21%) participants in the guselkumab Q8W arm and 24/50 (48%) participants in the placebo arm qualified for early escape at Week 16.Baseline demographics and disease characteristics were generally similar between the overall COSMOS population and the biomarker cohort (Supplementary Table 